Cargando…
Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy
Oral amoxicillin/clavulanate is a community workhorse antibiotic, routinely prescribed for respiratory tract infections, skin infections as well as urinary tract infections (UTIs). Multiple adult and paediatric dose formulations of amoxicillin/clavulanate are available in different parts of the worl...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954971/ https://www.ncbi.nlm.nih.gov/pubmed/33306184 http://dx.doi.org/10.1007/s40121-020-00374-7 |
_version_ | 1783664170852417536 |
---|---|
author | Veeraraghavan, Balaji Bakthavatchalam, Yamuna Devi Sahni, Rani Diana |
author_facet | Veeraraghavan, Balaji Bakthavatchalam, Yamuna Devi Sahni, Rani Diana |
author_sort | Veeraraghavan, Balaji |
collection | PubMed |
description | Oral amoxicillin/clavulanate is a community workhorse antibiotic, routinely prescribed for respiratory tract infections, skin infections as well as urinary tract infections (UTIs). Multiple adult and paediatric dose formulations of amoxicillin/clavulanate are available in different parts of the world. In adult formulations, clavulanic acid dose is restricted to 125 mg because of tolerability issues. Despite its popular use for 40 years, few pharmacokinetic/pharmacodynamic (PK/PD) studies were undertaken to justify the doses and breakpoints currently in use for various infections. Clavulanate has a minimal role in the combination’s use for respiratory infections. In the context of rising extended spectrum beta-lactamase (ESBL) prevalence globally, empirical and overuse of orally administered amoxicillin/clavulanate may select resistance in Gram-negative pathogens. The susceptibility test methods and interpretive criteria differ between the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST). Third-generation oral cephalosporins such as ceftibuten or cefpodoxime can be combined with amoxicillin/clavulanate to tackle UTIs involving ESBL producing Escherichia coli and Klebsiella spp. Clinicians who routinely prescribe amoxicillin/clavulanate in outpatient settings should be aware of potential benefits and limitations of this combination. |
format | Online Article Text |
id | pubmed-7954971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-79549712021-03-28 Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy Veeraraghavan, Balaji Bakthavatchalam, Yamuna Devi Sahni, Rani Diana Infect Dis Ther Commentary Oral amoxicillin/clavulanate is a community workhorse antibiotic, routinely prescribed for respiratory tract infections, skin infections as well as urinary tract infections (UTIs). Multiple adult and paediatric dose formulations of amoxicillin/clavulanate are available in different parts of the world. In adult formulations, clavulanic acid dose is restricted to 125 mg because of tolerability issues. Despite its popular use for 40 years, few pharmacokinetic/pharmacodynamic (PK/PD) studies were undertaken to justify the doses and breakpoints currently in use for various infections. Clavulanate has a minimal role in the combination’s use for respiratory infections. In the context of rising extended spectrum beta-lactamase (ESBL) prevalence globally, empirical and overuse of orally administered amoxicillin/clavulanate may select resistance in Gram-negative pathogens. The susceptibility test methods and interpretive criteria differ between the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST). Third-generation oral cephalosporins such as ceftibuten or cefpodoxime can be combined with amoxicillin/clavulanate to tackle UTIs involving ESBL producing Escherichia coli and Klebsiella spp. Clinicians who routinely prescribe amoxicillin/clavulanate in outpatient settings should be aware of potential benefits and limitations of this combination. Springer Healthcare 2020-12-11 2021-03 /pmc/articles/PMC7954971/ /pubmed/33306184 http://dx.doi.org/10.1007/s40121-020-00374-7 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Commentary Veeraraghavan, Balaji Bakthavatchalam, Yamuna Devi Sahni, Rani Diana Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy |
title | Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy |
title_full | Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy |
title_fullStr | Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy |
title_full_unstemmed | Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy |
title_short | Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy |
title_sort | orally administered amoxicillin/clavulanate: current role in outpatient therapy |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954971/ https://www.ncbi.nlm.nih.gov/pubmed/33306184 http://dx.doi.org/10.1007/s40121-020-00374-7 |
work_keys_str_mv | AT veeraraghavanbalaji orallyadministeredamoxicillinclavulanatecurrentroleinoutpatienttherapy AT bakthavatchalamyamunadevi orallyadministeredamoxicillinclavulanatecurrentroleinoutpatienttherapy AT sahniranidiana orallyadministeredamoxicillinclavulanatecurrentroleinoutpatienttherapy |